(Q37818230)

23 August 2017

1 reference

title

Exploration of synthetic lethal interactions as cancer drug targets (English)

1 reference

23 August 2017

Hendrik J Kuiken

1

1 reference

23 August 2017

Roderick L Beijersbergen

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

11

1 reference

23 August 2017

page(s)

1789-1802

1 reference

23 August 2017

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Timeline: Chemotherapy and the war on cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

The Role of cis-Platinum in Solid-Tumor Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Part II: Hodgkin's lymphoma--diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Choosing anticancer drug targets in the postgenomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Tissue repair and stem cell renewal in carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

21 January 2018

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Signaling networks assembled by oncogenic EGFR and c-Met

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

From oncogene to network addiction: the new frontier of cancer genomics and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Non-oncogene addiction and the stress phenotype of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Ras oncogenes: split personalities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Essential role for oncogenic Ras in tumour maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Reversible tumorigenesis by MYC in hematopoietic lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Principles for the buffering of genetic variation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Integrating genetic approaches into the discovery of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

PARP inhibition: PARP1 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Exploiting synthetic lethal interactions for targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Functional profiling of the Saccharomyces cerevisiae genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Systematic mapping of genetic interaction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Exploring the conservation of synthetic lethal genetic interaction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

A global analysis of genetic interactions in Caenorhabditis elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Evolutionary plasticity of genetic interaction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Utilizing RNA interference to enhance cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

A system for stable expression of short interfering RNAs in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Cancer proliferation gene discovery through functional genomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Profiling essential genes in human mammary cells by multiplex RNAi screening

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

A loss-of-function RNA interference screen for molecular targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

IRF4 addiction in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant {beta}-Catenin Activation in Colon Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Targeting polo-like kinase 1 for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Synthetic lethal screen identification of chemosensitizer loci in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Identification of Modulators of TRAIL-Induced Apoptosis via RNAi-Based Phenotypic Screening

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

21 January 2018

It's Diagnostics, Stupid

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.131

21 January 2018

Identifiers

DOI

10.2217/FON.10.131

1 reference

23 August 2017

1 reference